| 吴昊,石杨杨,梅雅婷,周颖,申震,吴大保.新辅助化疗对晚期卵巢癌患者疗效及预后分析[J].中国临床保健杂志,2019,22(2):250-254. |
| 新辅助化疗对晚期卵巢癌患者疗效及预后分析 |
| Efficacy and prognosis of neoadjuvant chemotherapy in patients with advanced ovarian cancer |
| 投稿时间：2018-11-20 |
| DOI：10.3969/J.issn.1672-6790.2019.02.027 |
| 中文关键词: 卵巢肿瘤 放化疗,辅助 生活质量 病人满意度 |
| 英文关键词: Ovarian neoplasms Chemoradiotherapy,adjuvant Quality of life Patient satisfaction 〖FL |
| 基金项目:国家自然科学基金面上项目(81272881);安徽省科技攻关项目(1501041141)；吴阶平基金(320.6750,3) |
|
| 摘要点击次数: 6017 |
| 全文下载次数: 5155 |
| 中文摘要: |
| 目的 观察晚期卵巢癌患者接受新辅助化疗后的效果,探讨影响晚期卵巢癌患者预后的相关因素。 方法 回顾性分析接受新辅助化疗的30例晚期卵巢癌患者,比较患者接受新辅助化疗前后,行中间型减瘤手术前各项检查指标有无改善,减瘤手术情况,随访患者无进展生存期及总生存期,结合各项指标研究影响患者预后的相关因素。 结果 纳入患者接受3个标准疗程的新辅助化疗后,患者的卡氏(KPS)评分、血红蛋白量、血清白蛋白量、腹腔镜评分较化疗前有显著改善,腹水大量减少,胸水基本消失,原发肿瘤体积明显缩小；在影响患者预后的单因素分析中,完成新辅助化疗后血清CA125＜35 IU/L及减瘤满意是无进展生存期的有利因素,年龄≤60岁、国际妇产科协会(FIGO)分期:IIIC期、较低水平的血清CA125及减瘤满意有助于改善患者总生存期。 结论 新辅助化疗有助于改善患者术前状态,减小肿瘤负荷,缩小手术范围,提高满意减瘤水平,保有患者较好的术后生活质量。 |
| 英文摘要: |
| Objective To observe the effect of neoadjuvant chemotherapy on patients with advanced ovarian cancer,collect various clinical indicators during treatment,and explore the factors influencing the patients′ prognosis with advanced ovarian cancer. Methods Retrospective analysis was performed in 30 patients with advanced ovarian cancer who received neoadjuvant chemotherapy,and clinical indicators were compared before and after NACT to see whether all the examination indicators had been improved or not before the cytoreductive surgery.Intraoperative situation had been collected.Patients′ progression free survival and Overall survival were followed up.Related factors influencing the prognosis of patients were gathered in combination with various indicators. Results After three standard courses of neoadjuvant chemotherapy,the patients′ KPS score,hemoglobin volume,serum albumin volume and laparoscope score were significantly improved compared with those before treatment.Ascites greatly decreased,Hydrothorax basically disappeared,and primary tumor volume significantly decreased.In the univariate analysis affecting the prognosis of patients,serum CA125 level<35 IU/L after neoadjuvant chemotherapy and satisfaction with tumor reduction were favorable factors for the progression free survival.Age not more than 60 years old,FIGO stage:IIIC stage,low serum CA125 and satisfaction with tumor reduction could help improve the overall survival. Conclusion Neoadjuvant chemotherapy can improve preoperative status of patients,reduce tumor load,narrow surgical range,improve the level of satisfactory of tumor reduction,and maintain good postoperative quality of life. |
|
查看全文
|
| 关闭 |
|
|
|